Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.

Houssaini A, Assoumou L, Miller V, Calvez V, Marcelin AG, Flandre P.

PLoS One. 2013;8(3):e59014. doi: 10.1371/journal.pone.0059014. Epub 2013 Mar 21.

2.

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.

Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research.

AIDS. 2010 Jan 28;24(3):365-71. doi: 10.1097/QAD.0b013e32833338ba.

PMID:
19864933
3.

Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.

Assoumou L, Houssaïni A, Costagliola D, Flandre P; Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research.

J Antimicrob Chemother. 2010 Apr;65(4):752-60. doi: 10.1093/jac/dkq034. Epub 2010 Feb 17.

PMID:
20164199
4.

Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.

Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D; Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research.

J Infect Dis. 2008 Aug 15;198(4):470-80. doi: 10.1086/590156.

PMID:
18598191
5.

Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.

De Luca A, Giambenedetto SD, Trotta MP, Colafigli M, Prosperi M, Ruiz L, Baxter J, Clevenbergh P, Cauda R, Perno CF, Antinori A.

J Infect Dis. 2007 Dec 1;196(11):1645-53. Epub 2007 Oct 26.

PMID:
18008248
6.

Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.

Flandre P, Marcelin AG, Pavie J, Shmidely N, Wirden M, Lada O, Bernard MC, Molina JM, Calvez V.

Antivir Ther. 2005;10(4):479-87.

PMID:
16038473
7.

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.

Pediatr Infect Dis J. 2005 Jun;24(6):503-9.

PMID:
15933559
8.

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.

Fourati S, Malet I, Guenzel CA, Soulie C, Maidou-Peindara P, Morand-Joubert L, Wirden M, Sayon S, Peytavin G, Simon A, Katlama C, Benichou S, Calvez V, Marcelin AG.

Antiviral Res. 2012 Jan;93(1):167-74. doi: 10.1016/j.antiviral.2011.11.008. Epub 2011 Nov 25.

PMID:
22138483
9.

Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.

Kijak GH, Rubio AE, Pampuro SE, Zala C, Cahn P, Galli R, Montaner JS, Salomón H.

HIV Med. 2003 Jan;4(1):72-8.

10.

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.

AIDS. 1998 Jun 18;12(9):1015-20.

PMID:
9662197
11.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
12.

Clinically relevant genotype interpretation of resistance to didanosine.

Marcelin AG, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, Chiche D, Molina JM, Calvez V; AI454-176 Jaguar Study Team.

Antimicrob Agents Chemother. 2005 May;49(5):1739-44.

13.

Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.

Vingerhoets J, Nijs S, Tambuyzer L, Hoogstoel A, Anderson D, Picchio G.

Antivir Ther. 2012;17(8):1571-9. doi: 10.3851/IMP2275. Epub 2012 Aug 7.

PMID:
22869341
14.
15.

Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

de Mendoza C, Ramos JT, Ciria L, Fortuny C, García FJ, de José MI, Asensi F, Soriano V.

HIV Clin Trials. 2002 Jan-Feb;3(1):9-16.

PMID:
11819180
16.

An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

Capdepont S, Aurillac-Lavignolle V, Faure M, Dupon M, Morlat P, Ragnaud JM, Chêne G, Fleury H, Masquelier B; GECSA.

J Clin Virol. 2006 May;36(1):36-42. Epub 2006 Feb 28.

PMID:
16513416
17.

Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D; EuroSIDA Study; United Kingdom CHIC/United Kingdom HDRD Study.

PLoS One. 2011;6(11):e25665. doi: 10.1371/journal.pone.0025665. Epub 2011 Nov 16.

18.

Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA.

PLoS One. 2010 Jul 9;5(7):e11505. doi: 10.1371/journal.pone.0011505.

19.

Comparison of nine resistance interpretation systems for HIV-1 genotyping.

Stürmer M, Doerr HW, Staszewski S, Preiser W.

Antivir Ther. 2003 Jun;8(3):239-44.

PMID:
12924541
20.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group.

Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799.

PMID:
21685536

Supplemental Content

Support Center